← BeOne Medicines Ltd.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($119.2m) |
($93.1m)
+21.90%
|
($673.8m)
-623.67%
|
($948.6m)
-40.79%
|
($1.6b)
-68.34%
|
($1.4b)
+11.49%
|
($2.0b)
-41.78%
|
($881.7m)
+56.00%
|
($644.8m)
+26.87%
|
$286.9m
+144.50%
|
— | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($119.2m) | ($93.3m) | ($674.0m) | ($950.6m) | ($1.6b) | ($1.4b) | ($2.0b) | ($881.7m) | — | — | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | ($194k) | ($264k) | ($1.9m) | ($3.6m) | $0 | $0 | — | — | — | — | |
| Depreciation, Depletion and Amortization | — | $4.8m | $10.4m | $18.6m | $31.8m | $46.5m | $66.3m | $87.7m | $171.8m | $141.7m | $154.9m | |
| Depreciation | $1.9m | $4.3m | $9.0m | $17.3m | $30.9m | $44.7m | $62.3m | $80.4m | $166.9m | $131.6m | $148.4m | |
| Amortization of Intangible Assets | — | $250k | $894k | $1.3m | $846k | $1.7m | $4.0m | $7.2m | $4.8m | $10.1m | — | |
| Depreciation and amortization expense | $1.9m | $4.8m | $10.4m | $18.6m | $31.8m | $46.5m | $66.3m | $87.7m | $171.8m | $141.7m | $154.9m | |
| Amortization of research and development cost share liability | — | — | $0 | $0 | ($114.0m) | ($112.5m) | ($96.4m) | ($55.3m) | ($73.2m) | ($101.1m) | — | |
| Deferred Income Tax Expense (Benefit) | ($768k) | ($5.9m) | ($22.3m) | ($9.5m) | ($28.2m) | ($41.3m) | $3.5m | $687k | $26.0m | $9.5m | $9.5m | |
| Deferred Other Tax Expense (Benefit) | — | — | — | $0 | $0 | ($1.7m) | $2k | $0 | — | — | — | |
| Deferred income tax expense | ($768k) | ($5.8m) | ($21.9m) | ($9.2m) | ($27.8m) | ($41.1m) | $2.1m | $689k | $26.0m | $9.5m | $9.5m | |
| Share-based Payment Arrangement, Noncash Expense | $10.6m | $42.9m | $87.1m | $134.2m | $183.5m | $240.7m | $303.2m | $367.6m | $441.6m | $510.9m | $525.3m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | — | — | — | $24.2m | — | |
| Share-based Payment Arrangement, Expense | $10.6m | $42.9m | $87.1m | $134.2m | $183.5m | $240.7m | $303.2m | $367.6m | $441.8m | $510.2m | $525.3m | |
| Share-based compensation expense | $10.6m | $42.9m | $87.1m | $134.2m | $183.5m | $240.7m | $303.2m | $367.6m | $441.6m | $510.9m | $525.3m | |
| Payments of withholding taxes from share-based awards | — | — | — | — | — | — | — | $0 | $0 | ($24.2m) | — | |
| Equity Method Investment, Other than Temporary Impairment | — | — | — | — | — | — | — | $7.5m | $7.6m | — | — | |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Impairment of equity investments | — | — | — | — | — | — | — | $7.5m | $6.8m | $75.6m | — | |
| Income (Loss) from Equity Method Investments | — | — | — | — | $11.8m | $7.6m | ($22.0m) | ($16.2m) | — | — | — | |
| Other Nonoperating Income (Expense) | $443k | $11.5m | $2.0m | $7.2m | $37.5m | $15.9m | ($223.9m) | $307.9m | ($12.6m) | ($42.6m) | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | $29.4m | $11.6m | $29.8m | ($10.4m) | $423.0m | ($304.1m) | $188.3m | $329.4m | $165.0m | ($284.5m) | |
| Accounts receivable | $0 | ($29.4m) | ($11.6m) | ($29.8m) | $10.4m | ($423.0m) | $304.1m | ($188.3m) | ($329.4m) | ($165.0m) | ($284.5m) | |
| Increase (Decrease) in Inventories | — | $10.9m | $5.3m | $12.3m | $58.9m | $153.3m | $56.7m | $140.9m | $91.5m | $93.2m | ($218.3m) | |
| Inventories | $0 | ($10.9m) | ($5.3m) | ($12.3m) | ($58.9m) | ($153.3m) | ($56.7m) | ($140.9m) | ($91.5m) | ($93.2m) | ($218.3m) | |
| Increase (Decrease) in Accounts Payable | $2.7m | $55.3m | $23.5m | $2.2m | $95.8m | $20.0m | ($4.4m) | $21.5m | $121.5m | $79.8m | $111.0m | |
| Accrued expenses and other payables | $13.9m | $25.0m | $50.5m | $64.0m | $182.7m | $140.0m | $45.6m | $180.1m | $111.4m | $311.8m | — | |
| Purchase of in-process research and development included in accounts payable | $0 | $0 | $19.0m | $0 | $0 | $75.0m | $0 | $31.8m | $60.0m | $0 | — | |
| Deferred revenue | ($1.1m) | $37.0m | ($9.1m) | ($28.0m) | $0 | $407.7m | ($151.8m) | ($255.6m) | $633k | $1.3m | — | |
| Other assets | — | — | — | ($20.7m) | ($56.2m) | ($107.1m) | ($3.3m) | $12.1m | $45.1m | $37.2m | — | |
| Other liabilities | — | — | — | $6.2m | ($25.5m) | ($2.6m) | ($1.2m) | $587k | ($14.8m) | $19.0m | — | |
| Net Cash Provided by (Used in) Operating Activities | ($89.5m) |
$12.8m
+114.25%
|
($547.7m)
-4395.15%
|
($750.3m)
-36.98%
|
($1.3b)
-71.07%
|
($1.3b)
-1.19%
|
($1.5b)
-15.24%
|
($1.2b)
+22.66%
|
($140.6m)
+87.85%
|
$1.1b
+901.80%
|
$1.5b
+31.61%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $23.5m | $46.4m | $70.3m | $89.6m | $117.5m | $262.9m | $325.4m | $561.9m | $492.7m | $185.8m | ($175.1m) | |
| Gain (Loss) on Disposition of Property Plant Equipment | — | ($85k) | ($126k) | — | — | — | — | — | — | — | $596k | |
| Accruals for capital expenditures | $2.2m | $2.2m | $22.1m | $29.1m | $42.8m | $53.2m | $95.3m | $91.8m | $70.3m | $57.3m | — | |
| Gain (Loss) on Investments | — | — | — | — | — | — | — | — | — | ($596k) | $596k | |
| Payments to Acquire Investments | — | — | — | — | $5.7b | — | — | — | — | — | ($11.8m) | |
| Unrealized Gain (Loss) on Investments | — | — | — | — | — | — | — | — | ($24.0m) | — | $24.0m | |
| Loss on long-term investments | — | — | — | — | — | — | — | ($8.7m) | ($17.2m) | ($596k) | — | |
| Purchase of long-term investments | — | — | — | $0 | ($26.7m) | ($43.5m) | ($15.9m) | ($14.9m) | ($19.0m) | ($11.8m) | — | |
| Proceeds from sale or maturity of short-term investments | $183.7m | $423.8m | $2.2b | $1.9b | $2.8b | $3.1b | $1.6b | $673.2m | $2.7m | $3.4m | — | |
| Payments for (Proceeds from) Other Investing Activities | — | — | — | — | — | $0 | $0 | — | $2.9m | $1.2m | — | |
| Other investing activities | — | — | — | $0 | ($2.0m) | $0 | $0 | ($2.1m) | ($2.9m) | ($1.2m) | — | |
| Net cash (used in) provided by investing activities | ($221.8m) | ($356.3m) | ($637.6m) | $554.2m | ($3.2b) | $640.7m | $1.1b | $60.0m | ($548.4m) | ($276.2m) | — | |
| Net Cash Provided by (Used in) Investing Activities | ($221.8m) | ($356.3m) | ($637.6m) | $554.2m | ($3.2b) | $640.7m | $1.1b | $60.0m | ($548.4m) | ($276.2m) | ($182.5m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | — | — | $8.7m | $32.8m | — | $0 | $0 | $13.7m | $28.0m | $35.7m | ($43.6m) | |
| Payments of debt issuance costs | — | — | — | — | — | — | — | $0 | $0 | ($23.4m) | — | |
| Proceeds from Issuance of Common Stock | — | — | $0 | $0 | $4.2b | $50.0m | $0 | $0 | — | — | — | |
| Proceeds from (Payments for) Other Financing Activities | — | — | — | — | — | — | $0 | $0 | $3.0m | $0 | — | |
| Net Cash Provided by (Used in) Financing Activities | $380.9m |
$490.4m
+28.74%
|
$1.7b
+244.76%
|
$85.7m
-94.93%
|
$5.2b
+5972.39%
|
$3.6b
-30.10%
|
($19.0m)
-100.52%
|
$416.5m
+2295.34%
|
$193.4m
-53.55%
|
$1.1b
+447.66%
|
$1.1b
+5.79%
|
|
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $69.6m | $152.1m | $501.1m | ($119.9m) | $769.2m | $3.0b | ($507.9m) | ($689.1m) | ($547.2m) | $2.0b | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | $501.1m | ($119.9m) | $769.2m | $3.0b | ($507.9m) | ($689.1m) | ($547.2m) | $2.0b | $5.2b | |
| Cash, cash equivalents, and restricted cash, beginning of year | $87.5m | $239.6m | $740.7m | $620.8m | $1.4b | $4.4b | $3.9b | $3.2b | $2.6b | $4.6b | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | $740.7m | $620.8m | $1.4b | $4.4b | $3.9b | $3.2b | $2.6b | $4.6b | $5.2b | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $18.2m | $14.0m | ($69.4m) | ($8.1m) | ($51.7m) | $60.0m | $72.2m | |
| Short-term restricted cash | $0 | $0 | $14.5m | $288k | $307k | $328k | $196k | $11.5m | $9.3m | $41.3m | — | |
| Long-term restricted cash | $0 | $0 | $13.2m | $2.5m | $7.7m | $6.9m | $5.3m | $2.7m | $2.0m | $20.8m | — | |
| Effect of foreign exchange rate changes, net | $104k | $5.3m | ($4.1m) | ($9.5m) | $18.2m | $14.0m | ($69.4m) | ($8.1m) | ($51.7m) | $60.0m | — | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | $4.6m | $29.7m | $47.0m | — | — | — | — | — | — | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $826k | $1.3m | $2.2m | $4.3m | $44.1m | $30.0m | $25.2m | $19.8m | $19.7m | $34.4m | — | |
| Income Taxes Paid, Net | — | $29.3m | $12.4m | $9.0m | $10.6m | $15.7m | $29.5m | $56.0m | $69.4m | $100.7m | — | |
| Additional Financial Items | ||||||||||||
| Deconsolidation, Gain (Loss), Amount | — | — | — | — | $11.3m | — | — | — | — | — | — | |
| Equity Securities, FV-NI, Gain (Loss) | — | — | — | — | — | — | — | — | — | ($74.5m) | — | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | — | — | — | ($16.6m) | — | |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | — | — | — | — | — | — | ($57.9m) | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | — | — | $362.9m | $0 | $0 | — | |
| General and Administrative Expense | $20.1m | — | — | — | — | — | — | — | — | — | — | |
| Goodwill | — | $109k | $109k | $109k | $109k | $109k | $109k | — | — | — | $75.6m | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | ($119.2m) | — | — | — | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | $54k | $2.2m | ($15.8m) | $7.0m | ($17.7m) | ($25.2m) | $42.8m | $55.9m | $111.8m | $129.9m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | — | $58.2m | — | |
| Investment Income, Interest | — | — | — | — | — | — | — | — | — | $70.5m | — | |
| Proceeds from Noncontrolling Interests | — | $14.5m | $0 | $4.0m | $0 | $0 | — | — | — | — | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | — | — | $1.2b | — | — | — | — | — | |
| Acquired in-process research and development | $0 | $0 | $70.0m | $69.0m | $109.5m | $83.5m | $68.7m | $46.8m | $60.0m | $691k | — | |
| Non-cash interest expense | $121k | $7.0m | $7.8m | $8.0m | — | — | — | $0 | $0 | $14.9m | — | |
| Gain on BMS termination settlement | — | — | — | — | — | $0 | $0 | ($362.9m) | $0 | $0 | — | |
| Other items, net | — | $41k | ($9.9m) | ($9.4m) | $6.6m | $23.5m | $9.0m | ($6.0m) | $11.2m | ($3.0m) | — | |
| Purchase of in-process research and development | $0 | $0 | ($70.0m) | ($69.0m) | ($109.5m) | ($8.5m) | ($143.7m) | ($15.0m) | ($31.8m) | ($60.7m) | — | |
| Purchase of intangible assets | $0 | $0 | ($553k) | $0 | $0 | ($43.4m) | $0 | ($19.4m) | ($4.7m) | ($20.0m) | — | |
| Proceeds from sale of future royalties | — | — | — | — | — | — | — | $0 | $0 | $911.0m | — | |
| Proceeds from long-term loan | $12.0m | $0 | $42.3m | $67.5m | $110.2m | $16.8m | $37.4m | $22.5m | $9.1m | $850.6m | — | |
| Repayment of long-term loan | $0 | $0 | ($8.7m) | ($32.8m) | ($132.1m) | $0 | $0 | ($13.7m) | ($28.0m) | ($35.7m) | — | |
| Proceeds from short-term loans | $0 | $2.5m | $0 | $0 | $323.7m | $406.4m | $313.8m | $661.5m | $868.3m | $233.7m | — | |
| Repayment of short-term loans | $0 | ($2.5m) | $0 | $0 | ($12.2m) | ($321.8m) | ($417.1m) | ($309.6m) | ($704.2m) | ($1.0b) | — | |
| Proceeds from option exercises and employee share purchase plan | — | $4.6m | $29.7m | $47.0m | $93.1m | $92.8m | $47.0m | $55.7m | $45.4m | $196.3m | — | |
| Repayment of sale of future royalties liability | — | — | — | — | — | — | — | $0 | $0 | ($4.0m) | — | |
| Cash and cash equivalents | $87.5m | $239.6m | $712.9m | $618.0m | $1.4b | $4.4b | $3.9b | $3.2b | $2.6b | $4.5b | $2.8b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.